Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Alimera Sciences News

    3,58 $ -1,38% -0,05 $
    In : 3,3355 € | 17:31:52 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PVHE
    ISIN: US0162592028
    US-Symbol: ALIM
    Typ: Aktie

    Alimera Sciences News

    27.01.20 - PR Newswire
    Alimera Sciences, Inc 13D/A filing
    Alimera Sciences, Inc 13D/A filing PR Newswire
    11.12.19 - PR Newswire
    Almira Sciences, Inc 13D filing
    Almira Sciences, Inc 13D filing PR Newswire
    23.04.19 - ACCESSWIRE
    Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update
    Conference Call to be held Tuesday April 30, 2019 at 9:00am Eastern Time
    23.04.19 - ACCESSWIRE
    Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
    ATLANTA, GA / ACCESSWIRE / April 23, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
    04.04.19 - ACCESSWIRE
    Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer
    ATLANTA, GA / ACCESSWIRE / April 4, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
    25.03.19 - ACCESSWIRE
    Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe
    - Indication for treatment of non-​infectious posterior uveitis further supports the uniqueness of ILUVIEN to consistently and continuously deliver treatment to reduce the recurrence of ...
    21.03.19 - ACCESSWIRE
    Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait
    Kuwait Added to the Growing Number of Countries with Approval for ILUVIEN in the Middle East
    06.03.19 - ACCESSWIRE
    Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France
    France is a Significant Market for Intravitreal Steroid Use
    18.02.19 - ACCESSWIRE
    Alimera Sciences Reports Record Fourth Quarter and 2018 Results
    Fourth Quarter 2018 Highlights
    05.02.19 - ACCESSWIRE
    Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon
    Lebanon will be the second Middle Eastern country to approve ILUVIEN
    04.02.19 - ACCESSWIRE
    Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019
    ATLANTA, GA / ACCESSWIRE / February 4, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
    07.01.19 - ACCESSWIRE
    Alimera Sciences Affirms Record 2018 Revenues
    Anticipates 2018 GAAP Net Revenue in Excess of $45 Million
    17.12.18 - ACCESSWIRE
    Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
    The U.A.E. becomes the first country in the Middle East to obtain pricing approval
    29.11.18 - ACCESSWIRE
    Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
    Co-​founder Dan Myers Named Non–Executive Chairman
    26.11.18 - ACCESSWIRE
    Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)
    ATLANTA, GA / ACCESSWIRE / November 26, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ...
    09.11.18 - ACCESSWIRE
    Alimera Sciences to Present at Upcoming Investor Conferences
    ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
    05.11.18 - ACCESSWIRE
    Alimera Sciences Reports Third Quarter 2018 Results
    Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ...
    23.10.18 - ACCESSWIRE
    Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018
    ATLANTA, GA / ACCESSWIRE / October 23, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
    22.10.18 - ACCESSWIRE
    Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology
    ATLANTA, GA / ACCESSWIRE / October 22, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic ...
    17.09.18 - PR Newswire
    Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
    Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress "CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the ...

    Newssuche

    Videos

    09:30 Uhr +34,15%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »